ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer

[cafead]

via Lilly has yet to enter the injectable obesity market with its GIP/GLP-1 agonist Mounjaro, but oral drugs are already the next frontier. New data, which were apparently released accidentally yesterday, gave investors the first look at the group's oral GLP-1 contender orforglipron, which is in phase 3 development.

article source